ALK — Drug Target
All drugs that target ALK — marketed and clinical-stage. Includes 1 drug classes acting on this target.
Drug classes
Marketed (1)
- Lorlatinib with chemotherapy 2 · Pfizer · ALK inhibitor · Oncology
Phase 2 pipeline (6)
- ALK tree AIT 7 DU · ALK-Abelló A/S · ALK inhibitor · Oncology
ALK tree AIT 7 DU is a targeted therapy that works by inhibiting the anaplastic lymphoma kinase (ALK) protein. - Any FDA Approved ALK Inhibitors · Takeda · ALK inhibitor · Oncology
ALK tyrosine kinase inhibitor - Alectinib - Usual · Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair · ALK inhibitor · Oncology
Alectinib is an anaplastic lymphoma kinase (ALK) inhibitor that targets the ALK protein. - ALK tree AIT 1 DU · ALK-Abelló A/S · ALK inhibitor · Oncology
ALK tree AIT 1 DU is a targeted therapy that works by inhibiting the anaplastic lymphoma kinase (ALK) protein. - ARQ 501 · ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · ALK inhibitor · Oncology
ARQ 501 is a selective inhibitor of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase. - ASP2215 · Astellas Pharma Global Development, Inc. · ALK inhibitor · Oncology
ASP2215 is a selective and potent inhibitor of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase.